PMID: 6255284Jan 1, 1980

Bacillus subtilis-phage phi 1 overcomes host-controlled restriction by producing BamNx inhibitor protein

Molecular & General Genetics : MGG
O MakinoT Ando

Abstract

Bacillus amyloliquefaciens N produces two restriction enzymes, BamNI and BamNx. Subtilis-phage phi 1 is strongly restricted by BamNx. We isolated phi 1 rH, a mutant of phage phi 1, which overcame the BamNx-restriction by producing inhibitor. This inhibitor inactivated BamNx specifically and reversibly. The inhibitor directly interacted with BamNx and the inactivation might be the result of formation of a binary complex. The inhibitory activity was sensitive to treatment with trypsin. The molecular weight of the inhibitor protein was estimated to be approximately 20,000 daltons by gel filtration.

References

Jul 1, 1978·Nucleic Acids Research·J G Sutcliffe, G M Church
Oct 1, 1979·Molecular & General Genetics : MGG·B BehrensA T Ganesan
Aug 18, 1976·Biochimica Et Biophysica Acta·T Shibata, T Ando
Mar 1, 1979·Journal of Virology·E F WagnerM Schweiger
Jul 1, 1978·Nucleic Acids Research·P J GreeneH W Boyer
Jul 1, 1976·Journal of Virology·F W Studier, N R Movva
Nov 1, 1976·CRC Critical Reviews in Biochemistry·R J Roberts
Sep 5, 1975·Journal of Molecular Biology·G A Wilson, F E Young
Jan 1, 1974·Molecular & General Genetics : MGG·T Shibata, T Ando
Jan 1, 1971·Annual Review of Microbiology·H W Boyer
Jan 1, 1969·Journal of Virology·L Rutberg
Dec 1, 1968·Journal of Molecular Biology·U E Loening
Mar 1, 1965·Journal of Bacteriology·B E REILLY, J SPIZIZEN

Related Concepts

Natto Bacteria
Bacteriophages
DNA Restriction Enzymes
Viral Proteins

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.